Effects of high intensity interval walking training on dynapenia

Effects of high intensity interval walking training on muscle strength in dynapenic patients with diabetes. - Effects of high intensity interval walking training on muscle strength in dynapenic patients with diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040658

Enrollment

Registered

2020-09-01

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1 and Type 2 Diabetes

Interventions

High intensity interval walking training(combined with fast walking at 70% or more of estimated maximum oxygen intake and slow walking at 40%in 3 minutes each) for 5 months(more than 120 minute-interv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients with type 1 and type 2 diabetes, who are able to exercise at 70% intensity of peak heart rate

Exclusion criteria

Exclusion criteria: People with cardiac pacemaker People with joint pain and movement restriction at the knee and waist. People in another clinical study, within 2 months prior to the start of this study People who are unable to continue the intervention People treated with severe peripheral neuropathy, retinopathy, chronic kidney disease, or cardiovascular disease.

Design outcomes

Primary

Measure	Time frame
Knee extension strength The differences in outcome variables, measured in the pre-, middle (3-mounths), and post-intervention (5-months) periods.	—

Secondary

Measure	Time frame
Secondary outcome: gait speed, VO2 peak, Health related QOL, Other outcome: BMI, skeletal muscle mass index, grip strength, fall risk index, mini nutritional assessment, HbA1c, eGFR, physical activity, skin autofluorescence, urinary albumin, nutrition intake.	—

Countries

Japan

Contacts

Public ContactHiroyasu Mori

Tokushima University Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences

mori.hiroyasu@tokushima-u.ac.jp088-633-7587

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026